irampanel

Irampanel (BIIR 561) is a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist developed by Boehringer Ingelheim. It was primarily investigated as a neuroprotective agent for the treatment of acute ischemic stroke and as an anticonvulsant for epilepsy. The drug's mechanism involves binding to an allosteric site on the AMPA-type glutamate receptor, thereby inhibiting the excessive influx of sodium and calcium ions that leads to excitotoxic neuronal death during ischemic events. Despite progressing through Phase 1 and Phase 2 clinical trials, development was ultimately discontinued due to a lack of demonstrated clinical efficacy in stroke patients, a challenge common to many neuroprotective agents in this pharmacological class.

Other names

Irampanel